

COMPASS THERAPEUTICS, INC.  
80 Guest Street  
Suite 601  
Boston, Massachusetts 02135

September 4, 2024

**Via EDGAR Transmission**

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Re: Compass Therapeutics, Inc.: Registration Statement on Form S-3 filed August 30, 2024 (File No. 333-281891)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “**Act**”), Compass Therapeutics, Inc. (the “**Company**”) hereby requests that the effective date of the above-referenced registration statement (the “**Registration Statement**”) be accelerated to September 6, 2024, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact Finnarr Murphy of Goodwin Procter LLP at (212) 459-7257.

Sincerely,  
Compass Therapeutics, Inc.

/s/ Thomas Schuetz

---

Thomas Schuetz  
Chief Executive Officer

cc: Thomas Schuetz, *Compass Therapeutics, Inc.*  
Jonathan Anderman, *Compass Therapeutics, Inc.*  
Richard Hoffman, Esq., *Goodwin Procter LLP*  
Finnarr Murphy, Esq., *Goodwin Procter LLP*